Dr. Ramalingam on Treatment Parameters for Osimertinib in Lung Cancer

Video

Suresh S. Ramalingam, MD, FASCO, discusses the current treatment parameters for osimertinib in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.

Suresh S. Ramalingam, MD, FASCO, deputy director of Winship Cancer Institute of Emory University, discusses the current treatment parameters for osimertinib (Tagrisso) in EGFR-mutant non—small cell lung cancer and ongoing research with the agent.

Patients diagnosed with lung adenocarcinoma or nonsquamous lung cancer receive molecular testing, and treatment should be held until the results are given, explains Ramalingam. For patients with EGFR exon 19 or exon 21 mutations, the frontline therapy is osimertinib outside of a clinical trial.

An ECOG trial examining osimertinib plus bevacizumab (Avastin) versus osimertinib alone will soon launch and give insight on combining another targeted agent with the best-in-class TKI inhibitor, says Ramalingam. Research is also looking into understanding the mechanisms of resistance to osimertinib and developing novel approaches to delay or overcome resistance, concludes Ramalingam.

<<< View more from the 2020 Winter Lung Cancer Conference

Related Videos
Raj Singh, MD
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology